View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 25, 2016updated 13 Jul 2022 10:15am

Transition doses first patient in Phase ll trial of TT701 to treat prostate cancer

Transition Therapeutics (Transition) has dosed the first patient in a Phase ll trial of its selective androgen receptor modulator (SARM) drug candidate TT701.

Transition Therapeutics (Transition) has dosed the first patient in a Phase ll trial of its selective androgen receptor modulator (SARM) drug candidate TT701.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The study will assess the efficacy and safety of TT701 in improving the symptoms of androgen deficiency, including sexual symptoms, fatigue / low vitality, and physical dysfunction in men with prostate cancer who have undergone radical prostatectomy for organ-localised prostate cancer.

The Phase ll clinical trial is being conducted at Brigham and Women’s Hospital (BWH), US, led by principal investigator Dr Shalender Bhasin from BWH and will enrol up to 125 subjects at selected specialised clinical sites including BWH.

BWH research programme in men’s health: aging and metabolism director Shalender Bhasin said: "Sexual dysfunction, fatigue and other distressing symptoms of testosterone deficiency can greatly reduce the quality of life for men who have undergone radical prostatectomy for organ localised disease.

"The dosing of the first patient in this study is expected to generate a payment of $500,000 to Lilly."

"Therefore, the ability to treat these symptoms safely is an important unmet need."

The company stated that its wholly-owned subsidiary, Transition Therapeutics Ireland has exclusively licensed worldwide rights to the TT701 drug candidate from Eli Lilly and Company (Lilly).

The dosing of the first patient in this study is expected to generate a payment of $500,000 to Lilly.

Transition further noted that prostate cancer is the most common malignancy in American men, accounting for 29% of all diagnosed cancers and around 13% of all cancer deaths.

Its incidence is on the rise, partly due to increased screening with Prostate-specific antigen (PSA).

The majority of these men have low-grade, organ-confined prostate cancer and good prospects of long-term survival.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena